0001465818-16-000103.txt : 20160422 0001465818-16-000103.hdr.sgml : 20160422 20160422135801 ACCESSION NUMBER: 0001465818-16-000103 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20160422 DATE AS OF CHANGE: 20160422 EFFECTIVENESS DATE: 20160422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HedgePath Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001042418 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 541641133 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-261874 FILM NUMBER: 161586269 BUSINESS ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVENUE STREET 2: SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 BUSINESS PHONE: (813) 864-2559 MAIL ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVENUE STREET 2: SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 FORMER COMPANY: FORMER CONFORMED NAME: COMMONWEALTH BIOTECHNOLOGIES INC DATE OF NAME CHANGE: 19970714 D 1 primary_doc.xml X0707 D LIVE 0001042418 HedgePath Pharmaceuticals, Inc. 324 SOUTH HYDE PARK AVENUE SUITE 350 TAMPA FL FLORIDA 33606 (813) 864-2559 DELAWARE COMMONWEALTH BIOTECHNOLOGIES INC Corporation true Nicholas J. Virca 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Executive Officer Garrison J. Hasara, CPA 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Executive Officer Frank E. O'Donnell, Jr., MD 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Executive Officer Director Samuel P. Sears, Jr. 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Director W. Mark Watson, CPA 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Director Stefan J. Cross 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Director R. Dana Ono, MD 324 SOUTH HYDE PARK AVENUE Suite 350 Tampa FL FLORIDA 33606 Director Pharmaceuticals Decline to Disclose 06c false 2016-04-11 false true true true false 0 5500000 600000 4900000 false 3 0 true 0 true The Company may retain FINRA member placement agents and will pay standard market commissions and other compensation to such agents. 0 true The proceeds from this Offering will be used for general corporate purposes, which may include executive compensation. false HedgePath Pharmaceuticals, Inc. /s/Nicholas J. Virca Nicholas J. Virca Chief Executive Officer 2016-04-20